These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 7678686)

  • 41. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
    Nademanee K; Singh BN
    Am J Cardiol; 1990 Jan; 65(2):53A-57A; discussion 65A-66A. PubMed ID: 2403735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of electrophysiologic properties between responders and non-responders to DL-sotalol among patients with ventricular tachyarrhythmia. Importance of the lack of a reverse use-dependent effect on ventricular refractoriness to responders.
    Naitoh N; Yamaura M; Tagawa M; Aizawa Y
    Jpn Heart J; 1998 Sep; 39(5):619-30. PubMed ID: 9925993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative electrophysiologic findings between responders and nonresponders to class III antiarrhythmic drugs among patients with ventricular tachyarrhythmia.
    Naitoh N; Washizuka T; Takahashi K; Miyajima T; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):307-19. PubMed ID: 9711182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency-dependent electrophysiologic effects of d,l-sotalol and quinidine and modulation by beta-adrenergic stimulation.
    Sager PT; Behboodikhah M
    J Cardiovasc Electrophysiol; 1996 Feb; 7(2):102-12. PubMed ID: 8853020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias.
    Watanabe H; Chinushi M; Washizuka T; Sugiura H; Hirono T; Aizawa Y; Komura S; Hosaka Y; Tanabe Y; Furushima H; Aizawa Y
    Circ J; 2006 May; 70(5):583-7. PubMed ID: 16636494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease.
    Young GD; Kerr CR; Mohama R; Boone J; Yeung-Lai-Wah JA
    Am J Cardiol; 1994 Apr; 73(9):677-82. PubMed ID: 8166065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy of cibenzoline in preventing PES induction of ventricular tachycardia in the dog.
    Keren G; Tepper D; Butler B; Miura D; Aogaichi K; Somberg J
    J Clin Pharmacol; 1984 Oct; 24(10):466-72. PubMed ID: 6511989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias.
    Brachmann J; Schöls W; Beyer T; Montero M; Enders B; Kübler W
    Eur Heart J; 1993 Nov; 14 Suppl H():85-7. PubMed ID: 8293757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction.
    Kassotis J; Sauberman RB; Cabo C; Wit AL; Coromilas J
    J Cardiovasc Electrophysiol; 2003 Nov; 14(11):1233-44. PubMed ID: 14678141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.
    Leite LR; Fenelon G; Simoes A; Silva GG; Friedman PA; de Paola AA
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):567-73. PubMed ID: 12875414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation between the effective refractory period and activation-recovery interval calculated from the intracardiac unipolar electrogram of humans with and without dl-sotalol treatment.
    Chinushi M; Tagawa M; Kasai H; Washizuka T; Abe A; Furushima H; Aizawa Y
    Jpn Circ J; 2001 Aug; 65(8):702-6. PubMed ID: 11502045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
    Anderson KP; Bigger JT; Freedman RA
    Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
    Kuchar DL; Garan H; Venditti FJ; Finkelstein D; Rottman JN; McComb J; McGovern BA; Ruskin JN
    Am J Cardiol; 1989 Jul; 64(1):33-6. PubMed ID: 2741811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
    Kopelman HA; Woosley RL; Lee JT; Roden DM; Echt DS
    Am J Cardiol; 1988 May; 61(13):1006-11. PubMed ID: 3284316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest.
    Singh SN; Cohen A; Chen YW; Wish M; Thoben-O'Grady L; Peralba J; Gottdiener J; Fletcher RD
    Am J Cardiol; 1988 Sep; 62(7):399-402. PubMed ID: 2458026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cibenzoline for high-frequency ventricular arrhythmias: a short-term comparison with quinidine and a long-term follow-up.
    Palakurthy PR; Maldonado C; Sohi G; Flowers NC
    J Clin Pharmacol; 1987 Apr; 27(4):283-7. PubMed ID: 3680585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Electrophysiologic properties of cibenzoline in Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia].
    Kühlkamp V; Ickrath O; Schmid F; Mayer F; Haasis R; Seipel L
    Z Kardiol; 1989 Oct; 78(10):640-6. PubMed ID: 2686251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs.
    Chézalviel F; Weissenburger J; Guhennec C; Jagueux M; Davy JM; Vernhet L; Simandoux V; Poirier JM; Cheymol G
    J Cardiovasc Pharmacol; 1993 Feb; 21(2):212-20. PubMed ID: 7679154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
    Dorian P; Newman D; Berman N; Hardy J; Mitchell J
    J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.